A recently published finding has reported that ABCC5 exerted a protumor effect to promote the phosphorylation of AR at Ser81 by CDK1 and activated the AR downstream target genes and promoted the malignant progression and enzalutamide resistance of prostate cancer [37], although it was unclear if ABCC5 transcriptionally promoted the AR expression and how it improved the drug resistance. The gene discussed is ABCC5; the disease is prostate carcinoma.